Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New use of fumigacin type steroids in producing medicine for anti-drug fast bacteria

A technology of fumagillic acid and drug-resistant bacteria, applied in the field of medicine, can solve problems such as the combination and use of fusidic acid and various antibiotics not involved, achieve obvious synergistic antibacterial effect, reduce side effects and adverse reactions, and achieve significant synergy synergistic effect

Inactive Publication Date: 2007-04-11
CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Rio Pharmaceutical Products Co., Ltd. has applied for a patent (publication number CN 1378554) on the preparation method, drug combination and use of fusidic acid derivative 17,20-dihydrofusidic acid, but it does not involve fusidic acid and poly Combination and application of antibiotics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of fumigacin type steroids in producing medicine for anti-drug fast bacteria
  • New use of fumigacin type steroids in producing medicine for anti-drug fast bacteria
  • New use of fumigacin type steroids in producing medicine for anti-drug fast bacteria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 The in vitro antibacterial activity assay and antibacterial activity comparison of fumagic acid / chloramphenicol composition to clinical drug-resistant Staphylococcus aureus

[0036] 1 Materials and methods

[0037] 1.1 Clinical drug-resistant strains:

[0038] The clinical drug-resistant strains were multidrug-resistant Staphylococcus aureus (Staphylococcus.aureus) isolated from clinical patients by the Laboratory Department of the West China First Affiliated Hospital of Sichuan University, and the bacterial numbers were 13929, 12334, 11931, 12352, 12798, and 12760. These isolated strains were subcultured and used in this example.

[0039] 1.2 Drugs and reagents:

[0040] Erythromycin, streptomycin, chloramphenicol, kanamycin, gentamicin, and tetracycline are products of Amresco Company, biochemically pure; penicillin sodium is penicillin sodium for injection from Harbin Pharmaceutical Group General Pharmaceutical Factory, and the batch number is C 04071091...

Embodiment 2

[0051] Example 2 The in vitro antibacterial activity assay and antibacterial activity comparison of fumagic acid / erythromycin composition to clinical drug-resistant Staphylococcus aureus

[0052] According to the experimental method of Example 1, the antibacterial activity of erythromycin and fumonic acid / erythromycin composition against clinical drug-resistant Staphylococcus aureus was determined, and the results are shown in Table 2.

[0053] antibiotic name

Erythromycin MIC(μg / ml)

Fumonic acid (μg / ml)

0

1

2

4

try

test

Bacteria

name

say

Staphylococcus aureus 12334

Staphylococcus aureus 11931

Staphylococcus aureus 12352

Staphylococcus aureus 12798

Staphylococcus aureus 12760

1000

500

2000

2000

2000

16

8

64

125

500

0.25

0.125

1

2

8

0.0625

0.0625

0.0625

0.0625

0.0625

[0054] The above exp...

Embodiment 3

[0056] Example 3 The in vitro antibacterial activity assay and antibacterial activity comparison of the fumagillin / streptomycin composition to clinical drug-resistant Staphylococcus aureus

[0057] The antibacterial activity of streptomycin and fumonic acid / streptomycin composition against clinical drug-resistant Staphylococcus aureus was determined according to the experimental method of Example 1, and the results are shown in Table 3.

[0058] antibiotic name

Streptomycin MIC(μg / ml)

Fumonic acid (μg / ml)

0

1

2

4

test

Bacteria name

say

Staphylococcus aureus 12352

Staphylococcus aureus 12798

Staphylococcus aureus 12760

4

8

128

2

4

64

0.125

0.25

0.5

0.0625

0.0625

0.0625

[0059] The above experimental results show that the fumagic acid / streptomycin composition has a stronger antibacterial activity against clinical drug-resistant Staphylococcus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
transmittivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a new uses of helvolicacid sterides in making drugs of antibiotic-resistant microbes, including helvolicacid, fusidic acid and its salt and salt hydrates acceptable in pharmacology, compound of ester or prodrug with single or multi-antibiotic, applying to preparation of drugs of antibiotic-resistant microbes.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a new application of combining a fumagillin-type steroid and antibiotics in the manufacture of anti-drug-resistant bacteria drugs. Background technique [0002] Due to the widespread use of antibiotics and the rapid evolution of microorganisms, multiple drug resistance mechanisms are widely spread in pathogenic bacteria, resulting in a decline in the clinical efficacy of various antibiotics. (Christopher Walsh. Molecular mechanisms that conferantibacterial drug resistance. Nature, 406:775-781 2000) At present, the problem of drug resistance of certain drug-resistant pathogenic bacteria, especially Gram-positive bacteria (such as Staphylococcus aureus), is becoming more and more serious . They are not only highly resistant to a single antibiotic, but also often resistant to multiple antibiotics at the same time, making clinical treatment very diffic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61K31/7048A61K31/43A61K31/65A61P31/04
Inventor 秦岭官家发李伯刚范成英廖连华何开泽张国林
Owner CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com